HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific...
Hence then, the article about akeso announces first patient enrollment in phase iii trial of ivonescimab for pancreatic cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer )
Also on site :
- Grimes to Star in the First-Ever AI-Generated Film Coming to Theaters: Watch a Clip
- Thousands of affidavit ballots outstanding in Mississippi Senate election. Campaigns prepare for legal fight
- What ‘Legend of Zelda’ Superfan Jon Batiste Thinks of ‘Ocarina of Time’ Remake and the Game’s Iconic Score